主要促进因子超家族成员2a在肝细胞癌组织中的表达及其临床意义

doi:10.3969/j.issn.1004-616x.2024.03.004

Abstract

Abstract: OBJECTIVE：To investigate expression of the major facilitator superfamily domain-containing protein 2a (MFSD2A) in hepatocellular carcinoma (HCC) tissues，and its correlation with clinical characteristics and prognosis of HCC patients. METHODS：The transcriptome data from 424 cases of HCC and 50 adjacent non-cancerous tissues，along with relevant clinical information were downloaded from The Cancer Genome Atlas (TCGA) database. Using a bioinformatics platform，expression of MFSD2A across various cancer types were compared. Association between MFSD2A expression and prognosis in HCC patients were evaluated using the Kaplan-Meier Plotter database. Additionally，a protein-protein interaction network of MFSD2A was constructed using the STRING database，related genes were retrieved using the GEPIA2 database，and pathway enrichment was analyzed to explore the molecular function of MFSD2A. Immunohistochemistry was performed to validate the expression of MFSD2A protein in HCC tumor tissues. RESULTS：Analysis of the TCGA data revealed significant differences in MFSD2A gene expression levels across various tissues. Specifically，MFSD2A was significantly under expressed in HCC tissues compared to adjacent tissues (P<0.01). Moreover，the expression increased in the over 60 age group (P=0.014)，in the G1 pathological grade group (P<0.01)，and in the group with AFP blood levels ≤400 ng/mL (P<0.01). High expression of MFSD2A was associated with significantly prolonged overall survival (P=0.008)，progression-free survival (P=0.008)，and recurrence-free survival (P=0.016) in patients. MFSD2A and its interacting proteins primarily participated in lipid metabolism-related PPAR signaling pathways. Immunohistochemistry analyses indicated that patients with high MFSD2A expression had better prognosis (P=0.016) compared to those with low expression，and serum AFP levels decreased with increasing MFSD2A scores. CONCLUSION：Low expression of MFSD2A was observed in HCC tissues and was associated with poor prognosis in patients. The results indicate that MFSD2A inhibited the progression of HCC by regulating hepatic lipid metabolism，and suggest that it may be a therapeutic target for hepatocellular carcinoma.

Key words: MFSD2A, hepatocellular carcinoma, prognosis, AFP, lipid metabolism

CLC Number:

R735.7

MA Sheng, WANG Xijun, LIU Zhenrong, WANG Yaru, HU Nan, RONG Weiqi, XIAO Ting. The expression and clinical significance of MFSD2A in hepatocellular carcinoma[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 187-194.

References

[1] SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249.
[2] CHAUDHARY K, POIRION O B, LU L Q, et al. Multimodal meta-analysis of 1, 494 hepatocellular carcinoma samples reveals significant impact of consensus driver genes on phenotypes[J]. Clin Cancer Res, 2019, 25(2): 463-472.
[3] ZHANG H J, ZHANG W Y, JIANG L Y, et al. Recent advances in systemic therapy for hepatocellular carcinoma[J]. Biomark Res, 2022, 10(1): 3.
[4] ARAVALLI R N, STEER C J. Immune-mediated therapies for liver cancer[J]. Genes, 2017, 8(2): 76.
[5] NGUYEN L N, MA D L, SHUI G H, et al. Mfsd2a is a transporter for the essential omega-3 fatty acid docosahexaenoic acid[J]. Nature, 2014, 509(7501): 503-506.
[6] ESER OCAK P, OCAK U, SHERCHAN P, et al. Overexpression of Mfsd2a attenuates blood brain barrier dysfunction via Cav-1/Keap-1/Nrf-2/HO-1 pathway in a rat model of surgical brain injury[J]. Exp Neurol, 2020, 326: 113203.
[7] GUEMEZ-GAMBOA A, NGUYEN L N, YANG H B, et al. Inactivating mutations in MFSD2A, required for omega-3 fatty acid transport in brain, cause a lethal microcephaly syndrome [J]. Nat Genet, 2015, 47(7): 809-813.
[8] PU W J, ZHANG H, HUANG X Z, et al. Mfsd2a+ hepatocytes repopulate the liver during injury and regeneration[J]. Nat Commun, 2016, 7: 13369.
[9] SHI X, HUANG Y M, WANG H Y, et al. MFSD2A expression predicts better prognosis in gastric cancer[J]. Biochem Biophys Res Commun, 2018, 505(3): 699-704.
[10] TIWARY S, MORALES J E, KWIATKOWSKI S C, et al. Metastatic brain tumors disrupt the blood-brain barrier and alter lipid metabolism by inhibiting expression of the endothelial cell fatty acid transporter Mfsd2a[J]. Sci Rep, 2018, 8(1): 8267.
[11] GYŐRFFY B. Survival analysis across the entire transcriptome identifies biomarkers with the highest prognostic power in breast cancer[J]. Comput Struct Biotechnol J, 2021, 19: 4101-4109.
[12] SZKLARCZYK D, GABLE A L, NASTOU K C, et al. The STRING database in 2021: customizable protein-protein networks, and functional characterization of user-uploaded gene/measurement sets[J]. Nucleic Acids Res, 2021, 49(D1): D605-D612.
[13] TANG Z F, KANG B X, LI C W, et al. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis[J]. Nucleic Acids Res, 2019, 47(W1): W556-W560.
[14] MAZIÈRES J, BRUGGER W, CAPPUZZO F, et al. Evaluation of EGFR protein expression by immunohistochemistry using H-score and the magnification rule: re-analysis of the SATURN study[J]. Lung Cancer, 2013, 82(2): 231-237.
[15] LIU T F, WANG J L, TONG Y, et al. Integrating network pharmacology and animal experimental validation to investigate the action mechanism of oleanolic acid in obesity[J]. J Transl Med, 2024, 22(1): 86.
[16] BEN-ZVI A, LACOSTE B, KUR E, et al. Mfsd2a is critical for the formation and function of the blood-brain barrier[J]. Nature, 2014, 509(7501): 507-511.
[17] PRIETO-SÁNCHEZ M T, RUIZ-PALACIOS M, BLANCOCARNERO J E, et al. Placental MFSD2a transporter is related to decreased DHA in cord blood of women with treated gestational diabetes[J]. Clin Nutr, 2017, 36(2): 513-521.
[18] ANGERS M, ULDRY M, KONG D, et al. Mfsd2a encodes a novel major facilitator superfamily domain-containing protein highly induced in brown adipose tissue during fasting and adaptive thermogenesis[J]. Biochem J, 2008, 416(3): 347-355.
[19] SHANG J W, YAMASHITA T, TIAN F, et al. Chronic cerebral hypoperfusion alters amyloid-β transport related proteins in the cortical blood vessels of Alzheimer’s disease model mouse [J]. Brain Res, 2019, 1723: 146379.
[20] WEI J P, QIN L X, FU Y, et al. Long-term consumption of alcohol exacerbates neural lesions by destroying the functional integrity of the blood-brain barrier[J]. Drug Chem Toxicol, 2022, 45(1): 231-238.
[21] WANG Z X, LIU C H, HUANG S, et al. Wnt signaling activates MFSD2A to suppress vascular endothelial transcytosis and maintain blood-retinal barrier[J]. Sci Adv, 2020, 6(35): eaba7457.
[22] CHOW B W, GU C H. Gradual suppression of transcytosis governs functional blood-retinal barrier formation[J]. Neuron, 2017, 93(6): 1325-1333.e3.
[23] LOBANOVA E S, SCHUHMANN K, FINKELSTEIN S, et al. Disrupted blood-retina lysophosphatidylcholine transport impairs photoreceptor health but not visual signal transduction [J]. J Neurosci, 2019, 39(49): 9689-9701.
[24] SÁNCHEZ-CAMPILLO M, RUIZ-PASTOR M J, GÁZQUEZ A, et al. Decreased blood level of MFSD2a as a potential biomarker of Alzheimer’s disease[J]. Int J Mol Sci, 2019, 21(1): 70.
[25] SPINOLA M, FALVELLA F S, COLOMBO F, et al. MFSD2A is a novel lung tumor suppressor gene modulating cell cycle and matrix attachment[J]. Mol Cancer, 2010, 9: 62.
[26] LEGER C, QUIRIÉ A, MÉLOUX A, et al. Impact of exercise intensity on cerebral BDNF levels: role of FNDC5/irisin[J]. Int J Mol Sci, 2024, 25(2): 1213.
[27] KOTSILITI E. CIDEB variants protect against liver disease[J]. Nat Rev Gastroenterol Hepatol, 2022, 19(10): 624.

The expression and clinical significance of MFSD2A in hepatocellular carcinoma

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	ZHANG Yi, GAO Han, ZHENG Zhanyue, TAN Qitao, YANG Minli, SUN Yan. Screening of key genes for prognosis of glioma based on public databases [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 195-201.
[2]	SONG Zhenming, YU Yunliang, YANG Jinmei, LIU Kun, GAI Chanchan, MA Chunyu. Prognostic value of P2RX1 in patients with ovarian serous carcinoma and its role in immune infiltration mechanisms [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(3): 208-218.
[3]	FU Yongqing, XU Sanhui, ZHAO Yan, WANG Lili. Relationships between SPP1, DEC1, C1QTNF6 and clinicopathologic outcomes of oral squamous cell carcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 107-111,117.
[4]	TONG Jing, WANG Dan. Expression and significance of miR-544a in patients with colorectal cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(2): 124-128,137.
[5]	XUE Song, HU Jiahai, DONG Xiangning. Expression of PGAM5 and its association with clinicopathologic characteristics in pancreatic cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 29-34.
[6]	WANG Kefang, CHEN Yu, WU Chenyu, LIU Mei, WANG Lijie, TIAN Jianguang, ZHOU Xiaohui, XU Lan. Clinicopathological roles of IL-17A and estrogen receptors α, β in epithelial ovarian cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2024, 36(1): 42-47.
[7]	ZHU Wenbiao, QIU bo, XIE Shoucheng, XIAO Huanqin, LIU Gaomin. Expression and clinical significance of transmembrane protein 79 in hepatocellular carcinoma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 426-430.
[8]	YANG Shangying, HUANG Mingxiang, XU Dexin, LIU Jiafu, CHEN Xinfu. Expression of DNAJB4 and association with immune infiltration and prognosis in non-small cell lung cancer [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(6): 467-472.
[9]	GUO Wenjing, DENG Hui, SONG Ping, ZHANG Mengxian. Expression and biological functions of TGFBI in glioma [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 341-348.
[10]	WEI Laifeng, HONG Chaoqun, CHEN Liuyi, XU Yiwei, WU Fangcai. Prognostic value of nomogram of laboratory inflammation-related indicators in tongue squamous cell carcinoma patients with surgery [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(5): 366-373.
[11]	YANG Chengqing, CUI Yonghui, ZHENG Ziheng. Expression and clinical significance of miR-653-5p in colon cancer patients [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 261-265.
[12]	LIU Ruixue, ZHANG Liwei. Expression and significance of AMPK esophageal squamous cell carcinoma among Kazakhs [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(4): 285-291.
[13]	LIU Ying, WANG Rui, GUO Xiao, DONG Lüli, ZHANG Yan, ZHAO Yinhuan, DU Yun. Relationships between DNA ploidy abnormality and EGFR mutation in pleural effusions, and their effects on prognosis of lung adenocarcinomas [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 178-182,186.
[14]	WANG Ping, WANG Huayong, WANG Hao, LEI Dajun. Expression of miR-193a and miR-21-5p in serum exosomes from osteosarcoma patients and their clinical values [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(3): 197-201.
[15]	CHEN Shuang, PENG Zhongrui, WU Zhenwen, GUO Dongbei, SUN Meijun, LI Lei. Protective effects of angelica keiskei chalcones on acute alcoholic liver injury in mice [J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2023, 35(2): 95-101.